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Abstract
Background:  A frequent manifestation of advanced lung cancer is malnutrition, timely
identification and treatment of which can lead to improved patient outcomes. Bioelectrical
impedance analysis (BIA) is an easy-to-use and non-invasive technique to evaluate changes in body
composition and nutritional status. We investigated the prognostic role of BIA-derived phase angle
in advanced non-small cell lung cancer (NSCLC).
Methods: A case series of 165 stages IIIB and IV NSCLC patients treated at our center. The Kaplan
Meier method was used to calculate survival. Cox proportional hazard models were constructed
to evaluate the prognostic effect of phase angle, independent of stage at diagnosis and prior
treatment history.
Results: 93 were males and 72 females. 61 had stage IIIB disease at diagnosis while 104 had stage
IV. The median phase angle was 5.3 degrees (range = 2.9 – 8). Patients with phase angle <= 5.3 had
a median survival of 7.6 months (95% CI: 4.7 to 9.5; n = 81), while those with > 5.3 had 12.4 months
(95% CI: 10.5 to 18.7; n = 84); (p = 0.02). After adjusting for age, stage at diagnosis and prior
treatment history we found that every one degree increase in phase angle was associated with a
relative risk of 0.79 (95% CI: 0.64 to 0.97, P = 0.02).
Conclusion: We found BIA-derived phase angle to be an independent prognostic indicator in
patients with stage IIIB and IV NSCLC. Nutritional interventions targeted at improving phase angle
could potentially lead to an improved survival in patients with advanced NSCLC.
Background
Worldwide, lung cancer is the most common form of can-
cer, with an incidence of 1.35 million new cases per year,
and 1.18 million deaths, with the highest rates in Europe
and North America. Non-small cell lung cancer (NSCLC)
accounts for about 80% of all lung cancers [1].
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Malnutrition is a frequent manifestation in patients with
advanced NSCLC and is a major contributor to morbidity
and mortality [2]. Malnutrition is characterized by
changes in cellular membrane integrity and alterations in
fluid balance [3]. As a result, measurement of body com-
position is an important component of overall nutritional
evaluation in cancer patients [4-6].
Historically, nutritional status has been evaluated by vari-
ous objective measures, including anthropometric (e.g.
weight change, arm muscle circumference, triceps skin-
fold thickness) and laboratory (serum albumin, transfer-
rin assays and nitrogen balance studies) measurements. In
the clinical setting, anthropometric methods are not ideal
because they are time-consuming and require well-trained
staff. Some of the objective measures such as serum albu-
min are likely to be influenced by many non-nutritional
factors [7-10]. Furthermore, some objective indicators
such as serum albumin have long half-lives, thus, assess-
ing changes in the nutritional status over a short period of
time is challenging. A less common tool to assess nutri-
tional status, called Bioelectrical Impedance Analysis
(BIA), can overcome some of these challenges. BIA is an
easy-to-use, non-invasive, and reproducible technique to
evaluate changes in body composition.
BIA has been validated for the assessment of body compo-
sition and nutritional status in a variety of patient popu-
lations including cancer [2,5,11-21]. BIA measures body
component resistance (R) and capacitance (Xc) by record-
ing a voltage drop in applied current [22]. Resistance is the
restriction to the flow of an electric current, primarily
related to the amount of water present in the tissues.
Capacitance is the resistive effect produced by the tissue
interfaces and cell membranes [23]. Capacitance causes
the current to lag behind the voltage creating a phase shift,
which is quantified geometrically as the angular transfor-
mation of the ratio of capacitance to resistance, or the
phase angle [24].
Phase angle reflects the relative contributions of fluid
(resistance) and cellular membranes (capacitance) of the
human body. By definition, phase angle is positively asso-
ciated with capacitance and negatively associated with
resistance [24]. Lower phase angles suggest cell death or
decreased cell integrity, while higher phase angles suggest
large quantities of intact cell membranes [25]. Phase angle
has been found to be a prognostic marker in several clini-
cal conditions such as human immunodeficiency virus
infection, liver cirrhosis, chronic obstructive pulmonary
disease, hemodialysis, sepsis, lung cancer [25-30]. Previ-
ously, we had demonstrated the prognostic role of phase
angle in advanced colorectal and pancreatic cancer
[31,32]. We also recently demonstrated the prognostic
role of phase angle in breast cancer [33]. The primary
objective of this study, which builds upon our prior
research work in this area, was to evaluate the association
of BIA-derived phase angle with survival in patients with
advanced NSCLC.
Methods
A retrospective chart review was performed on a consecu-
tive case series of 165 stages IIIB and IV NSCLC patients
treated at Cancer Treatment Centers of America (CTCA)®
at Midwestern Regional Medical Center (MRMC) between
January 2001 and May 2006 (this is the same time as that
mentioned in our previous breast cancer manuscript). The
patients were identified from the MRMC tumor registry.
Only patients with a histologically confirmed diagnosis of
stages IIIB and IV NSCLC were included in this study. The
study was approved by the Institutional Review Board at
MRMC.
Phase angle was measured using BIA at presentation to
our hospital as part of the overall nutritional assessment
of the patient. For a detailed description of statistical
methods, please refer to our recently published manu-
script on breast cancer [33]. For the purpose of univariate
analysis, phase angle measurements were categorized
using SPSS into 2 mutually exclusive groups with median
= 5.3 as the cut-off. In our previous research on breast can-
cer, we had similarly categorized phase angle measure-
ments using the median value as the cut-off [33]. For the
purpose of multivariate analyses (linear Cox regression),
phase angle was treated as a continuous variable.
Results
At the time of this analysis, 111 patients had expired and
54 were censored, as shown in Table 1. The median age at
diagnosis was 56 years (standard deviation – 9.1 years;
range 30 – 78 years). The median phase angle was 5.3
degrees (standard deviation – 1.1 degrees; range = 2.9 – 8
degrees). Figure 1 depicts a histogram showing the distri-
bution of phase angle scores.
Table 1: Baseline characteristics
Characteristic Categories Number Percent (%)
Sex Male 93 56.4
Female 72 43.6
Vital Status Expired 111 67.3
Censored1 54 32.7
Prior Treatment Progressive disease 85 51.5
History Newly diagnosed 80 48.5
Stage at Diagnosis Stage III 61 37.0
Stage IV 104 63.0
1 Patients who reached the end of their follow-up without 
experiencing death.
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Table 2 shows the univariate survival analysis of different
prognostic factors. Phase angle, tumor stage and treat-
ment history were found to be statistically significantly
associated with survival while gender was not. Every one
year increase in age at diagnosis was associated with a rel-
ative risk of 1.01 (95% CI: 0.98 to 1.03, P = 0.63). The
mean age at diagnosis was 58.1 years (standard deviation
– 8.3 years) and 53.1 years (standard deviation – 9.1
years) for the "below median" and "above median" phase
angles groups respectively, the difference being statisti-
cally significant (p < 0001). Similarly, the mean phase
angle in degrees was 5.6 (standard deviation – 1.1) and
A histogram depicting the distribution of phase angle Figure 1
A histogram depicting the distribution of phase angle.
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Table 2: Univariate Kaplan-Meier survival analysis
Variable Survival in months Log-rank score P-value
Phase Angle
• <= 5.3 7.6 (4.7 to 9.5) 6.3 0.02
• >5.3 12.4 (10.5 to 18.7)
Gender
• Male 8.7 (5.7 to 11.8) 2.9 0.08
• Female 12.2 (4.9 to 19.4)
Tumor Stage
• Stage IIIB 16.8 (9.4 to 24.3) 9.0 0.003
• Stage IV 7.7 (5.9 to 9.3)
Treatment History
• Newly diagnosed 14.3 (9.9 to 20.6) 9.8 0.002
• Progressive disease 6.8 (4.5 to 9.1)
N = 165BMC Cancer 2009, 9:37 http://www.biomedcentral.com/1471-2407/9/37
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4.9 (standard deviation – 0.94) for "males" and "females"
respectively, the difference being statistically significant (p
< 0001).
Figure 2 shows the survival curves for the two categories of
the phase angle. Patients with phase angle <= 5.3 had a
median survival of 7.6 months (95% CI: 4.7 to 9.5; n =
81), while those > 5.3 had 12.4 months (95% CI: 10.5 to
18.7; n = 84); the difference being statistically significant
(p = 0.02).
Table 3 summarizes the results of multivariate Cox regres-
sion analyses. Multivariate Cox modeling, after adjusting
for age, stage at diagnosis and prior treatment history
found that every one degree increase in phase angle was
associated with a relative risk of 0.79 (95% CI: 0.64 to
0.97, P = 0.02).
Discussion
The identification of prognostic factors in advanced
NSCLC is of considerable importance for clinical manage-
ment of the disease. Tumor stage remains the single most
important prognostic factor in advanced NSCLC. The cur-
Survival stratified by phase angle categories with cutoff of 5.3 Figure 2
Survival stratified by phase angle categories with cutoff of 5.3. Each drop in a probability curve indicates one or more 
events in that group. Vertical lines indicate censored patients, i.e., those who reached the end of their follow-up without expe-
riencing death.
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rent study was undertaken to investigate if BIA-derived
phase angle, a potential indicator of nutritional status,
could predict survival in advanced NSCLC cancer.
This study demonstrated that phase angle is a strong pre-
dictor of survival in advanced NSCLC after controlling for
the effects of age, stage at diagnosis and prior treatment
history. A similar study conducted in patients with
advanced lung cancer stratified the patient cohort by the
mean phase angle of 4.5 degrees. Interestingly, patients
with phase angle less than or equal to 4.5 degrees had a
significantly shorter survival than those with phase angle
greater than 4.5 degrees [34]. In our previous study in
stage IV colorectal cancer patients, we found that phase
angle above the median cut-off of 5.6 was associated with
better survival [32]. Similarly, in stage IV pancreatic can-
cer, phase angle above the median cut-off of 5 was associ-
ated with improved survival [31].
This study adds to the growing body of evidence regarding
the clinical applications of BIA derived phase angle
beyond its use in body composition equations. Although
the biological meaning of phase angle is not well under-
stood, it reflects not only body cell mass, but is also one
of the best indicators of cell membrane function, related
to the ratio between extracellular water and intracellular
water [23]. Schwenk et al. has hypothesized that phase
angle could possibly be interpreted as a global marker of
malnutrition in HIV infected patients [30]. In another
study conducted on HIV-infected patients, it was argued
that phase angle reflects the integrity of vital cell mem-
branes [28]. In patients with liver cirrhosis, phase angle
was speculated to be a marker of clinically relevant malnu-
trition characterized by both increased extracellular mass
and decreased body cellular mass [25]. In advanced lung
cancer, phase angle was speculated to be an indicator of
altered tissue electrical properties [34]. In spite of lack of
standardized cut-off values, phase angle seems to play an
important role as a marker of morbidity and mortality in
a wide range of disease conditions, with higher phase
angle reflecting a general indicator of wellness [23].
Limitations of this study relate to the BIA technique and
retrospective study design. This study, because of its retro-
spective nature, relies on data not primarily meant for
research. One potential limitation of the BIA approach for
estimating body composition is the reliance on regression
models, derived in restricted samples of human subjects,
which limits the usefulness of the derived model in other
patients who differ from the original sample in which the
model was developed [35,36]. However, in our study, we
looked at phase angle which does not depend on regres-
sion equations to be calculated, thereby eliminating a
large source of random error [3]. It has also been sug-
gested that the variability of direct bioimpedance meas-
ures (resistance, capacitance, and phase angle) depends
on age, gender, and body mass characteristics of the study
population which could possibly limit the extrapolation
of the model [23,35,37]. A review article by Foster et al.
argued that although the correlation between whole-body
impedance measurements and body composition is
experimentally well established, the reason for the success
of the impedance technique is much less clear [38].
Finally, because we used linear Cox regression, there is a
possibility of a floor effect with phase angle rarely, if ever,
reaching much below 2 degrees. As a result, a degree dif-
ference in phase will may have a much greater relative risk
between 2 and 3 degrees than 7 and 8 degrees.
The other limitations of the study are very similar to the
limitations described in our breast cancer manuscript
[33].
Conclusion
In summary, our study has demonstrated the prognostic
significance of phase angle in advanced NSCLC after con-
trolling for the effects of stage at diagnosis and prior treat-
ment history.
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